INTRODUCTION {#S1}
============

One major obstacle to curing the global HIV epidemic is the reservoir of latently infected resting CD4+ T cells ([@R13]; [@R28]; [@R68]). Under antiretroviral therapy (ART), HIV viral load is undetectable in the plasma of infected individuals. Upon removal of ART, the viral load rapidly rebounds back to pretreatment levels of viremia due to reactivation of the latent reservoir ([@R22]). Reactivation from latency involves production and spread of virions to target-rich lymph node niches unprotected by ART ([@R83]).

Researchers have worked extensively on the mechanisms and regulation of latency ([@R68]; [@R69]) and on drug treatments to both reactivate and remove cells harboring latent provirus (i.e., the shock-and-kill strategy) ([@R19]; [@R23]; [@R81]). Strategies to reactivate the latent reservoir are plagued by severe challenges, including (1) incomplete reactivation of non-inducible provirus ([@R38]), (2) uncertainty regarding clearance or death of cells after latent reversal ([@R24]; [@R73]), and (3) coupling of migration and reactivation of latently infected T cells, causing additional viral spread in cell niches ([@R7]; [@R58]). Recent efforts have used an alternative block-and-lock strategy toward silencing latency into a chronically inactive state ([@R5]; [@R19]; [@R47]). Another approach, direct removal of the latent reservoir, is challenged by our inability to identify latent cells at low expression levels. To address this, researchers have pursued identification of novel biomarkers for viral persistence ([@R31]; [@R39]).

Gene expression fluctuations play an important role in determining when a virus shifts between latency and activation ([@R88], [@R89]). Studies of gene expression bursts at levels of transcription and translation in human fibroblasts, and cell-free gene expression systems reveal a correlation between gene expression bursts and cell reaction volume ([@R9]; [@R61]). Here, a burst is defined as the number of mRNA produced per transcriptional activity pulse of the promoter during episodic transcription (transcriptional burst) or the number of proteins produced per mRNA lifetime (translational burst). Both transcriptional and translational bursts contribute to total gene expression bursts ([@R20]; [@R45]; [@R60]). The authors show that fluorescence measured by the abundance of GFP increases with the size of a cell-free gene expression reactor, similar to increases of mRNA levels of genes in larger human fibroblasts ([Figure S1](#SD1){ref-type="supplementary-material"}) ([@R9]; [@R61]). Observed increases are described by increased burst size, not by increased burst frequency (the transition rate of an inactive promoter into active transcribing state k~on~), both of which can increase abundance levels ([@R18]; [@R45]; [@R54]; [@R76]; [@R78]). In addition, burst frequency (k~on~ or F) has been shown to depend on cell cycle and decreases after DNA replication in the late G2 phase ([@R61]; [@R80]). Additional studies have investigated the coupling of gene expression noise to growth rate and cell cycle of yeast ([@R46]).

Previous studies have shown that cell size influences other cell functions. A preexisting intracellular variation dependent on the volume of *Escherichia coli* cells has been shown to bias lambda phage developmental fate before infection ([@R82]). Additional studies reveal that the lysis-lysogeny decision of bacteriophage λ depends on both bacterial host-cell size and MOI ([@R15]; [@R92]). The postinfection decision of the phage is initially made at the single-virus level with additional infections contributing to an integrated decision between lysis and lysogeny of the targeted cell ([@R92]). The probability of entering the lysogeny state has also been shown to be inversely proportional to phage infection times ([@R15]).

Despite the low MOI of latently infected T cells, these examples of viral-host decision-making suggest the possibility of similar determinants existing in the reactivation-latency decision of latently integrated HIV in single human T cells. Here we show that cell size and cell cycle are involved in single-cell decision-making of HIV-infected T cells. Along with consistent burst size dependence on cell size for various housekeeping promoters ([Figure S1](#SD1){ref-type="supplementary-material"}), this suggests a general role in endogenous genetic systems.

RESULTS {#S2}
=======

Model of Cell Size-Based Initiation of HIV Feedback and Reactivation from Latency {#S3}
---------------------------------------------------------------------------------

To investigate whether HIV's shift from prolonged latency to reactivation could depend on cell size, we implemented a computational model consisting of the HIV long terminal repeat (LTR) promoter driving the expression of the HIV transactivator of transcription (Tat) ([Figure 1A](#F1){ref-type="fig"}). Activation of LTR transcription by Tat is a potent positive feedback loop required to exit the latent state ([@R88], [@R89]). The model consists of a 2-state episodic LTR promoter that is primarily in the inactive or non-transcribing state (k~off~ \>\> k~on~) and underlies expression of Tat autoregulation, regardless of whether it is active ([Figure 1A](#F1){ref-type="fig"}, bottom) or inactive ([Figure 1A](#F1){ref-type="fig"}, top). At low Tat levels ([Figure 1A](#F1){ref-type="fig"}, top), feedback is inactive and viral expression is described by the 2-state switching model with the active LTR state, switched at rate k~on~, where viral mRNA are transcribed at rate k~m~. This occurs before decay back to an inactive transcribing state at rate k~off~ ([@R45]; [@R62]; [@R76]). At high Tat levels produced by lower k~off~, LTR bound by Tat transcribes at an elevated transcription rate, initiates feedback, and leads to reactivation from latency. For inactive feedback, the number of mRNA produced per promoter activity pulse (k~m~/k~off~) in the transcribing state is defined as the transcriptional burst size (or B). Translation occurs at rate k~p~, and the number of proteins translated per mRNA lifetime (k~p~/γ~m~) is defined as the translational burst size (or b). Total expression burst size (B × b) is assumed to increase with cell size ([Figure 1A](#F1){ref-type="fig"}, left vertical arrow), and a range of burst sizes is assessed for evidence of increased cell-size-dependent transitions between the inactive to the active feedback state ([Figure 1A](#F1){ref-type="fig"}). This model has been previously used to understand the role of Tat feedback in HIV autonomy from host-cell state ([@R66]).

Analysis of gene expression fluctuations, or noise, has been a valuable tool to understand the stochastic viral switch of HIV ([@R88], [@R89]). Transcriptional bursting of the LTR promoter has been experimentally measured and modeled across the human genome, including noise modulation under diverse drug treatments ([@R6]; [@R18], [@R19], [@R21]; [@R78]). Translational bursting also contributes to total gene expression noise ([@R20]; [@R60]). Noise measurements from LTR expression can illustrate the dependence of total burst size (B × b) on cell size and be used for modeling size-dependent behavior ([Figure 1](#F1){ref-type="fig"}).

Total expression burst size of the inactive feedback 2-state promoter B × b is proportional to mean Tat protein levels and noise (quantified by the coefficient of variation squared (CV^2^)) using the following equations: $$\langle p\rangle = \frac{bBF}{\gamma_{p}},CV^{2} = \frac{b(1 + B)}{\left\langle p \right\rangle}$$ $$B = \frac{k_{m}}{k_{off}},\ F = K_{on},\ b = \frac{k_{p}}{\gamma_{m}},\ B \times b = \frac{k_{m}k_{p}}{k_{off}\gamma_{m}}$$

Here Tat protein is referred to as p; mRNA and protein are produced at rates k~m~ and k~p~ and degraded at rates γ~m~ and γ~p~, respectively; burst frequency is indicated as F; and other rates and burst definitions have been mentioned earlier. These equations have been previously derived under slow gene activation assumptions that k~off~ \>\> k~on~, k~off~ \>\> k~m~, k~off~ \>\> γ~p~, and k~m~ \>\> (γ~m~ + γ~p~) ([@R18]; [@R45]; [@R76]; [@R78]). For latently infected cells, the assumption that k~off~ \>\> k~on~ holds more than previous estimates for an active LTR promoter ([Table S1](#SD1){ref-type="supplementary-material"}).

With an assumed increasing power function dependence of total burst size (B × b) on cell size, stochastic simulations were performed using a power function for all cell volumes. Single-cell expression trajectories of larger cells surpassed Tat threshold levels needed for reactivation, while smaller cells remained latent (Figures [1B](#F1){ref-type="fig"} and[1C](#F1){ref-type="fig"}). [Figure 1C](#F1){ref-type="fig"} shows the number of cells reactivated and sorted by diameter. The result is compared to and normalized by a size distrbution (6--20 μm) of the total T cell population obtained experimentally ([Figure 1C](#F1){ref-type="fig"}, orange curve). Here B × b changes k~off~ and k~m~ simultaneously ([Figure 1A](#F1){ref-type="fig"}, upper versus lower), while additional cases of changing k~p~ and combinations of the three increase reactivation. The effect of Tat on the 2-state promoter switching model has been shown to effectively decrease k~off~ such that in the transition of Tat to higher levels and active feedback, transcriptional bursts and total burst size are increased ([@R67]).

In the inactive feedback model with low Tat levels, noise is inversely related to mean abundance ([Equation 1](#FD1){ref-type="disp-formula"}; [Figure 1D](#F1){ref-type="fig"}). Increases in transcriptional burst size (B) lead to a higher burst model line from which transcription can be initiated with activator drug treatments known to increase burst frequency (F) or the rate of switching into the active LTR state. Larger cells would surpass the threshold between promoter only and active feedback, while smaller cells would fall short.

Recently reported noise drug cocktails effectively exploit the same noise modulation strategy by using combination drug treatments to increase both B and F and achieve synergistic reactivation in latent cell populations ([Equation 1](#FD1){ref-type="disp-formula"}) ([@R19]). In the current study, natural heterogeneity of latent cell size varies in total burst size and a similar effect is achieved with a single-activator treatment to increase F and total \<p\>. Larger cell sizes are primed for stochastic reactivation before activator treatments. The model results show that cell-size-dependent total expression bursts are capable of determining between reactivated and latent states of HIV. This motivates our hypothesis that cell-size-dependent increases of burst size can determine the decision of HIV to reactivate from latency after activator drug treatment ([Figure 1D](#F1){ref-type="fig"}). If true, cell-size-dependent decision-making of HIV in single cells will be important for understanding stochastic design and heterogeneity in other biological systems and disease ([@R17]).

Gene Expression Bursts of the HIV LTR Promoter Increase with T Cell Size {#S4}
------------------------------------------------------------------------

To test whether larger cell sizes increase the HIV LTR burst size, we performed single-cell time-lapse fluorescence microscopy of Jurkat T cells infected with the LTR driving a short-lived 2-hr half-life GFP (d2GFP) ([@R18]). The greater the d2GFP fluorescence, the more viral protein and expression activity occurs. Imaging was performed on a clonal population of LTR-d2GFP for 14 hr ([STAR Methods](#S10){ref-type="sec"}). 3,037 single-cell trajectories were quantified over time for total fluorescent intensity and binned into ten cell size ranges ([Figure 2A](#F2){ref-type="fig"}, with mean bin diameter noted). For the 10 bins, the LTR-d2GFP Jurkats reveal that the larger the mean cell diameter, the greater the total fluorescence intensity (blue circles, [Figure 2B](#F2){ref-type="fig"}). The d2GFP intensity per unit volume shows no change across all cell diameters (orange squares, [Figure 2B](#F2){ref-type="fig"}). This is consistent with previous reports of increased transcription levels and transcriptional burst size with cell volume to maintain constant transcript concentrations ([@R61]). Noise was analyzed from the total fluorescent trajectories of the cells in each bin ([@R18]). Noise magnitude from finite-duration imaging (high-frequency coefficient of variation squared, or HF-CV^2^) ([Figure 2C](#F2){ref-type="fig"}) ([@R18]) and total burst size ([Figure 2D](#F2){ref-type="fig"}) increase with the mean diameter of each bin ([Figure 2A](#F2){ref-type="fig"}). Increasing noise magnitude with fluorescence indicates an increase in total burst size ([Equation 1](#FD1){ref-type="disp-formula"}) and was previously observed for the LTR at both mRNA and protein levels using both microscopy (HF-CV^2^ and CV^2^) and flow cytometry (CV^2^) ([@R18], [@R21]). The d2GFP reporter showed a constant degradation rate with cell size under cycloheximide treatment ([Figure S2](#SD1){ref-type="supplementary-material"}), and previous reports show that mRNA degradation stays constant with cell size ([@R61]). Total burst size (B × b) determined using [Equation 1](#FD1){ref-type="disp-formula"} showed a non-linear increase of up to a 10-fold change across the cell diameter range ([Figure 2D](#F2){ref-type="fig"}). To find the dependence of changes to total burst size with cell size, fold change of total burst size was fit with a power function (R^2^ = 0.99) ([Figure 2E](#F2){ref-type="fig"}). This was used to simulate the size-dependent increases of expression bursts from [Figure 1](#F1){ref-type="fig"}. All diameter measurements obtained by microscopy were verified using a Moxi Z automated cell analyzer (Orflo), which exploits the Coulter principle for cell count and size ([@R53]) ([Figure S3](#SD1){ref-type="supplementary-material"}).

High-frequency processing of noise (HF-CV^2^) ([@R18]; [@R89]) effectively high-pass filters total noise and focuses on modulations of intrinsic noise of the gene circuit. Low-frequency extrinsic noise from global resource fluctuations is filtered. HF-CV^2^ and CV^2^ have been shown to correlate and provide precise measurements of expected noise ([@R18], [@R21]; [@R89]).

To test whether cell-size-dependent burst size applies to additional promoters, Jurkat cells were randomly infected with the Ubiquitin C (UbC) housekeeping promoter at a low MOI (MOI = 1) expressing d2GFP (UbC-d2GFP). Polyclonal UbC-d2GFP revealed increased burst size with cell size ([Figure S1](#SD1){ref-type="supplementary-material"}). This suggests that cell-size-dependent total burst size is independent of integration site and occurs globally across the genome ([Figure S1](#SD1){ref-type="supplementary-material"}). This is consistent with increased burst size of housekeeping promoters quantified in human fibroblasts and their increases in burst size with cell size to maintain constant concentrations ([Figure S1](#SD1){ref-type="supplementary-material"}) ([@R61]). Finally, two Food and Drug Administration (FDA)-approved drug screens on Jurkats, one for cell size and one for noise, were compared ([Figure S4](#SD1){ref-type="supplementary-material"}) to examine the relationship between cell size modulation and noise-modulating drug treatments on the HIV LTR promoter. The screens reveal a correlation between noise enhancement and cell size, suggesting that exogenous treatments can modulate both cell size and HIV expression bursts.

Latent HIV Reactivates Exclusively in Larger T Cells while Smaller Cells Remain Silent {#S5}
--------------------------------------------------------------------------------------

To measure the size of latently infected cells at their moment of reactivation, a Jurkat latency model (JLat) consisting of full-length HIV with a frameshift mutation in *env* and GFP replacing the *nef* reading frame ([@R43]) was imaged using single-cell time-lapse fluorescence microscopy, similar to previous studies ([Figure 3A](#F3){ref-type="fig"}) ([@R18]; [@R89]). GFP is an indicator for latent cells switching to a reactivated state. Generation of JLat cell lines renders them GFP-- when untreated ([@R43]). Three clonal JLat cell populations (6.3, 9.2, and 15.4) were activated with tumor necrosis factor alpha (TNF-α) at the start of imaging (t = 0) and imaged every 10 min for 20--26 hr ([Figure 3A](#F3){ref-type="fig"}; [Video S1](#SD2){ref-type="supplementary-material"}; [STAR Methods](#S10){ref-type="sec"}). TNF-α is a potent activator of the LTR promoter by upregulating nuclear translocation of nuclear factor κB (NF-κB), which binds κB sites within the LTR enhancer ([@R26]) ([Figure S8](#SD1){ref-type="supplementary-material"}). JLat 9.2 has previously reactivated to \~30% after 24-hr induction with TNF-α ([@R7]; [@R43]; [@R81]). After imaging, individual reactivation events were segmented by image processing and detected and quantified over time for their mean fluorescent intensity, cell area, and equivalent diameter ([Figure 3A](#F3){ref-type="fig"}). Detected reactivation events were defined as cells having an intensity above a threshold determined by sample and substrate autofluorescence for at least 4 hr ([Figure 3B](#F3){ref-type="fig"}). A single intensity and cell size value (or equivalent diameter) were quantified for each reactivation event by averaging its time-dependent trajectory for 4 hr after first detection (Figures [3B--3D](#F3){ref-type="fig"} and [S5](#SD1){ref-type="supplementary-material"}).

The three JLats showed consistent reactivation in larger cells with a mean diameter of \~15 μm compared to a mean population diameter of \~12 μm ([Figure 3C](#F3){ref-type="fig"}). Cells lower than the mean population diameter showed no reactivation. To further demonstrate that reactivation of large cells occurs independently of the drug treatment used, we performed additional experiments using diverse reactivation treatments of trichostatin A (TSA); TSA+TNF-α; prostratin (Pro); Pro+TNF-α; and suberoylanilide hydroxamic acid (SAHA)+TNF-α, on JLat 9.2 and 15.4 (Figures [3D](#F3){ref-type="fig"} and [S6](#SD1){ref-type="supplementary-material"}; [STAR Methods](#S10){ref-type="sec"}). Consistent with TNF-α treatment, all cells reactivated in a larger cell diameter regime above the 12 mm mean population diameter. Mean cell diameters of reactivated cells ranged from 15.5 to 17.2 μm ([Figure 3D](#F3){ref-type="fig"}). As TNF-α treatment duration increased, reactivation events increased in cell diameter, intensity, and frequency at later detection times ([Figure S5](#SD1){ref-type="supplementary-material"}). Due to long (\>20 hr) cell doubling times and minimal measured changes to single-cell volumes (dV/dt) ([Figure S3](#SD1){ref-type="supplementary-material"}), this effect cannot be attributed to dynamic changes of burst size of individual cells during imaging. For example, total reactivation events of JLat 9.2 + TNF-α between 10 and 14 hr increased by 42% compared to 14 and 18 hr ([Figure S5](#SD1){ref-type="supplementary-material"}). Examining sub-populations of the total large cell range, mean intensity of cells with a diameter of 12--14 μm remains fairly constant, while diameters of 16--19 μm reactivate at later treatment durations with higher intensity ([Figure S5](#SD1){ref-type="supplementary-material"}). This suggests a size-dependent response to treatment within the large cell size regime.

To confirm that the detected reactivation events occurring in larger cells are not biased by sample preparation, imaging parameters, or cell state, we performed three control experiments. First, the diameter distribution of imaged cells from the LTR-d2GFP population from [Figure 2](#F2){ref-type="fig"} was quantified and yielded cell sizes as low as 6.75 μm ([Figure S6](#SD1){ref-type="supplementary-material"}), demonstrating our ability to image small cells. Second, JLat 15.4 was imaged and its reactivation diameter distribution was quantified after extended treatment to allow doubling of adult cells before preparing the imaging sample ([Figure S6](#SD1){ref-type="supplementary-material"}). For both controls, cell diameters reached similarly low levels, suggesting that the detected reactivation of larger cell sizes is not an artifact of the experimental design or processing. Finally, to rule out that larger latently infected cells are in a higher activated state than smaller cells, we investigated the dependence of the active Jurkat cell state on cell size. Immunofluorescent staining of the activation cell receptor CD69 was performed on two JLat populations treated with TNF-α for 24 hr and showed no dependence of T cell activation levels on cell size ([Figure S7](#SD1){ref-type="supplementary-material"}). TNF-α addition increases CD69 of JLat populations equally for all cell sizes. This shows that cell activation state is not correlated with cell size and cannot account for the observed latent reactivation occurring exclusively in larger cell sizes.

To investigate whether viral reactivation depends on nucleus volume (compared to cytoplasm volume), JLat 9.2 was treated with TNF-α+Pro and TNF-α+SAHA for 14 hr before staining with DAPI and imaging ([Figure 3E](#F3){ref-type="fig"}). Synergistic two-drug treatments increased the number of GFP+ events before cell doubling occurs at the 14-hr time point ([Figure 3E](#F3){ref-type="fig"}). Both the area-based equivalent diameter of DAPI-stained nuclei (purple-labeled pixels, [Figure 3E](#F3){ref-type="fig"}) and the total cell diameter based on GFP (red cell outline, [Figure 3E](#F3){ref-type="fig"}) from reactivated JLat cells were quantified ([STAR Methods](#S10){ref-type="sec"}). A bimodal distribution of nucleus diameter was observed for more than 28,000 quantified nuclei (gray, [Figure 3F](#F3){ref-type="fig"}). GFP+ cells reactivated in a similar range of nucleus diameters but showed an enrichment of about 2× cells with larger nuclei for both treatments (red, [Figure 3F](#F3){ref-type="fig"}). For GFP+ cells, nucleus diameter is positively correlated with total cell diameter and comprises most of the cell. This suggests that transcriptional burst (B) contributes to total burst size (B × b) in proportion to total cell size (Figures [2D](#F2){ref-type="fig"} and[3G](#F3){ref-type="fig"}).

Next, to assess the contribution of cytoplasm and translational bursts, we calculated the ratio of cytoplasm volume to nucleus volume for GFP+ cells (C:N ratio). Plotting C:N volume ratio versus total cell diameter shows values less than 1 for most reactivated cells (\~80%) ([Figure 3H](#F3){ref-type="fig"}). Along with a control showing that promoter fluctuations dominate noise measured in all cells ([Figure S2](#SD1){ref-type="supplementary-material"}), these results suggest that changes in total burst size (B × b) are dominated by changes in nucleus size and transcriptional bursts (B) are less influenced by changes in translational bursts (b).

Latently Infected Primary CD4+ T Cells Consistently Reactivate in Larger Cells {#S6}
------------------------------------------------------------------------------

To test whether size-dependent reactivation from latency is conserved in primary human CD4+ T cells infected with the JLat vector, sorted cells were adhered and imaged for 12--15 hr under treatment with a potent transcriptional activator combination, phorbol 12-myristate 13-acetate (PMA)+ionomycin, at the start of imaging ([Figure 4A](#F4){ref-type="fig"}). Examples of reactivating primary cells are shown ([Figure 4A](#F4){ref-type="fig"}; [Video S2](#SD3){ref-type="supplementary-material"}; [STAR Methods](#S10){ref-type="sec"}). A total of 805 reactivation events were detected from the infected CD4+ T cells from two donors and quantified for their 4-hr mean intensity and diameter (Figures [4B](#F4){ref-type="fig"} and [S8](#SD1){ref-type="supplementary-material"}). Most reactivation events had cell diameters greater than the mean diameters for the activated T cell population from each donor (red versus black distributions, [Figure 4B](#F4){ref-type="fig"}), and vertical dashed lines for both the active and the resting primary CD4+ T cell distributions represent mean cell diameters. The increased reactivation diameters of the primary CD4+ T cells are consistent with the observed reactivation of larger Jurkat cells ([Figure 3](#F3){ref-type="fig"}).

Unlike the JLat, reactivated primary cells did not increase in intensity with cell diameter ([Figure S8](#SD1){ref-type="supplementary-material"}). Reactivation intensity increased in the JLats only after 10 hr of imaging with TNF-α (Figures [3](#F3){ref-type="fig"} and [S5](#SD1){ref-type="supplementary-material"}), which is consistent with an \~10- to 12-hr time delay needed for NF-κB activation by TNF-α ([Figure S8](#SD1){ref-type="supplementary-material"}). Increased fluorescence intensity by delayed response to PMA+ionomycin treatment was not possible to capture, because imaging of primary cells was limited to 12--15 hr. However, fluorescence-activated cell sorting (FACS) of GFP+JLatd2GFP-infected CD4+ T cells treated for 48 hr with diverse activators ([Figure S8](#SD1){ref-type="supplementary-material"}) showed size-dependent intensity enhancement consistent with the assumed model (Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}, and [S8](#SD1){ref-type="supplementary-material"}).

To establish that resting and infected primary CD4+ T cells are unable to reactivate in smaller cell sizes, we performed additional microscopy experiments using PMA+ionomycin ([Figure 4C](#F4){ref-type="fig"}). Resting T cells infected with JLatd2GFP showed decreased cell sizes and no reactivation between 4 and 18 hr of imaging, both with and without pretreatment of PMA+ionomycin. Stimulated GFP-- sorted CD4+ cells from donor 1 revealed increased cell diameter and GFP+ cell counts. Cell viability of all infected cells was between 80% and 100% and assessed using propidium iodide (PI) staining.

Reactivation of HIV Latency Depends on Cell-Cycle Phase {#S7}
-------------------------------------------------------

Despite the idea that cell size would be naturally correlated with cell cycle, reports in fibroblasts have shown that all cell-cycle phases can exist throughout the range of cell sizes in a population ([@R61]). We have confirmed this in Jurkat T cells using a cell-cycle stain. TNF-α-treated JLats reveal no correlation between cell size and cell cycle ([Figure S7](#SD1){ref-type="supplementary-material"}). In addition to cell size-dependent transcriptional bursting, studies in mammalian cells have shown that transcriptional burst frequency (F or k~on~) decreases with cell-cycle progression (i.e., F~G1~ \> F~G2~) ([@R61]). Given the strict dependence of reactivation on larger cell size, we next investigated the dependence of reactivation of latency on cell cycle.

With reactivation occurring by combining increased transcriptional burst frequency (e.g., with TNF-α in [Figure 3C](#F3){ref-type="fig"}) and burst size, latent cells predisposed with higher burst frequency at earlier cell-cycle phases are predicted to synergize to higher reactivation levels when treated with an activator (Equations [1](#FD1){ref-type="disp-formula"} and [2](#FD2){ref-type="disp-formula"}; [Figure 5A](#F5){ref-type="fig"}) ([@R18], [@R19]; [@R78]). Conversely, treating cells with an activator at later cell-cycle phases is predicted to result in fewer threshold crossings due to lower burst frequency (i.e., F~G1+TNF-α~ \> F~G2+TNF-α~).

To test whether reactivation increases at earlier cell-cycle stages, we modified the computational model showing active feedback from [Figure 1A](#F1){ref-type="fig"} for the larger cell size (higher B model line) to have two burst frequencies corresponding to G1 and G2 phases (Figures [5A](#F5){ref-type="fig"} and[5B](#F5){ref-type="fig"}). Here F~G1~ was defined to be double F~G2~ ([Figure 5B](#F5){ref-type="fig"}) based on previously measured results ([@R61]), and G2 was simulated to have 2 copies of the gene ([Table S1](#SD1){ref-type="supplementary-material"}). Total burst size dependence on cell diameter was scanned similarly using the power function of [Figure 2E](#F2){ref-type="fig"}. Stochastic simulations show that reactivation of cells in both cell-cycle phases increases with diameter. G1 cells reach about double the reactivation compared to G2 cells ([Figure 5C](#F5){ref-type="fig"}).

To experimentally test the model prediction of increased reactivation at earlier cell cycles, we compared the cell-cycle distribution of reactivated JLat cells to their whole population distribution (both GFP+ and GFP-- cells) ([Figure 5D](#F5){ref-type="fig"}). JLat 9.2 and 15.4 were stimulated with TNF-α or TNF-α+SAHA for only 12 hr to exclude any measurement of GFP+ cells produced from doubling events after treatment, which could skew the cell-cycle distribution ([Figure S6](#SD1){ref-type="supplementary-material"}). DNA content using a phycoerythrin (PE)-conjugated cell-cycle stain and GFP expression was measured using flow cytometry ([Figure S9](#SD1){ref-type="supplementary-material"}). For JLat 9.2, treatment with TNF-α or TNF-α+SAHA indicates that reactivation occurs to some extent in all cell-cycle phases (red, [Figure 5D](#F5){ref-type="fig"}). Similar results were observed for JLat 15.4.

Cell-cycle phase-dependent reactivation was calculated by the ratio between GFP+-reactivated cells and all cells in the JLat population after normalization of each distribution by its integrated cell count ([Figure 5D](#F5){ref-type="fig"}). Ratios of normalized GFP+ to all cells were examined across the PE-Cy-5 range ([Figure 5E](#F5){ref-type="fig"}). A cell-cycle phase ratio value of 1 would mean that the number of cells expected to reactivate at a specific cell-cycle phase is consistent with an a *priori* assumption that reactivation occurs with equal probability across all cell-cycle phases of the latent population and would reject the hypothesis that G1 cells with higher burst frequency have increased reactivation ([Figure 5A](#F5){ref-type="fig"}). For TNF-α treatment, the ratio at G1 results in a \~4× increase from expected reactivation and a 2× increase for G2 ([Figure 5E](#F5){ref-type="fig"}). S phase shows a 60% decrease in the expected amount of reactivation. Reduced reactivation in the S phase is confirmed by TNF-α+SAHA treatment (Figures [5D](#F5){ref-type="fig"} and[5E](#F5){ref-type="fig"}). This is consistent with a reported role for S phase in stabilizing latency and providing a barrier for active replication of the virus ([@R29]; [@R85]). In contrast to TNF-α-treated cells (black, [Figure 5E](#F5){ref-type="fig"}), the amplified ratio in G1 is suppressed with TNF-α+SAHA treatment while the S and G2 phases of the ratio curve follow similar trends (black and purple, [Figure 5E](#F5){ref-type="fig"}). This is consistent with a reported G1 cell-cycle arrest by SAHA in different cell lines ([@R4]). It also motivates the active control and stochastic design of viral decision-making by modulating burst frequency for specific cell-cycle states ([@R19]; [@R17]; [@R54]).

Cell-Cycle Modulators Alter Synergistic Reactivation from Latency {#S8}
-----------------------------------------------------------------

To assess whether cell-cycle-dependent reactivation can be actively modulated, we performed treatments for 24 hr with an array of known cell-cycle-arresting compounds on JLats 9.2 and 15.4. Treatments included rapamycin, resveratrol or cytarabine, and 17β-estradiol known to arrest cell cycle in T cells at G1, S, and G2, respectively ([Figure 6A](#F6){ref-type="fig"}) ([@R30]; [@R40]; [@R41]; [@R70]; [@R93]). After cell-cycle arrest treatment for 12 hr, TNF-α was added to the cell-cycle arrest for an additional 12 hr. Cell-cycle states of reactivated GFP+ cells after cell-cycle arrest were compared to the distributions of JLats treated with only TNF-α (Figures [5D](#F5){ref-type="fig"} and[6B](#F6){ref-type="fig"}). Drug-treated cells showed high cell viability and no reactivation when treated with cell-cycle-arresting treatments alone ([Figure S10](#SD1){ref-type="supplementary-material"}). Cell-cycle phase distributions for the reactivated cells with treatments are shown in [Figures 6B--6E](#F6){ref-type="fig"}. Exposure to rapamycin resulted in reactivation in the G1 phase, which was calculated by the percentage of GFP+ cells detected by flow cytometry gating ([Figure S9](#SD1){ref-type="supplementary-material"}). GFP+ cells accumulated in the G1 phase compared to G2, and their distribution is plotted in red ([Figure 6B](#F6){ref-type="fig"}). Treatment with resveratrol resulted in an increase of activated cells in S phase and a decrease of cells in G1 and G2 phases ([Figure 6C](#F6){ref-type="fig"}). Although cytarabine also arrests T cells at S phase ([@R30]), treatment significantly blocked transition of cells from G1 to S phase and reactivation predominantly occurred in G1 ([Figure 6D](#F6){ref-type="fig"}). Treatment with 17β-estradiol resulted in a significant increase of 2.3× and 1.5× in G2 reactivation for JLat 9.2 and 15.4, respectively, compared to TNF-α treatment alone (Figures [6B](#F6){ref-type="fig"} and[6E](#F6){ref-type="fig"}). This effect was combined with a reduction of activated cells in G1 and S phases. However, these drugs alone may also change HIV expression through alternative mechanisms ([@R37]; [@R52]; [@R84]). These results demonstrate the possibility of active cell-cycle control for latent reactivation at specific cell-cycle phases. This presents an additional cell-state strategy to bias viral decision-making.

To test the possibility of reactivation with cell-cycle arrest, treatments combined with TNF-α were performed (Figures [6F](#F6){ref-type="fig"} and[6G](#F6){ref-type="fig"}). Cell cycle of JLat 9.2 and 15.4 was arrested with 24 hr of treatment, and TNF-α stimulation of cells was carried out either in combination with cell-cycle-arresting treatment for 24 hr or 12 hr after arrest was initiated. The percentage of reactivated GFP+cells with combined treatment was analyzed and compared to the percentage of cells reactivated with TNF-α alone (Figures [6F](#F6){ref-type="fig"} and[6G](#F6){ref-type="fig"}). 24-hr cell-cycle arrest and treatment with 12-hr activator showed synergy and increased reactivation in G1 compared to TNF-α treatment (red dashed line, [Figure 6F](#F6){ref-type="fig"}). G2 phase showed reduced synergy with reactivation comparable to TNF-α. For 24 hr of combined treatment, G1 displayed synergy, while G2 and S phases showed decreased reactivation levels, or antagonism to TNF-α. This is consistent with an expected decrease in burst frequency with cell-cycle progression compared to the increased frequency by TNF-α treatment alone ([Figure 6G](#F6){ref-type="fig"}).

Cell-cycle-dependent synergies for enhanced latent reactivation were further investigated using a previously reported FDA-approved noise enhancing compound library ([@R19]). A portion of the reported library is known to arrest cell cycle ([Figure 6H](#F6){ref-type="fig"}; [Table S2](#SD1){ref-type="supplementary-material"}). Previous measurements show that JLat 8.6 treated with TNF-α in combination with 18 cell-cycle-arresting noise enhancers results in cell-cycle-dependent synergy, consistent with the results observed here ([Figure 6H](#F6){ref-type="fig"}) ([@R19]). The results demonstrate that synergistic reactivation of latent cells is minimal in S and G2 but significantly increases for G1 and G1/S phases (p \< 0.05). This trend is consistent with F~G1+TNF-α~ \> F~G2+TNF-α~, as seen in Figures [6F](#F6){ref-type="fig"} and[6G](#F6){ref-type="fig"}.

DISCUSSION {#S9}
==========

Studies of stochastic gene expression have investigated the role of noise in diverse gene circuits, networks, and phenotypes ([@R3]; [@R63]). Extending the dependence of lambda phage developmental fate on host-cell volume before infection ([@R82]), we show that similar host-cell-dominating effects apply to infected human cells and demonstrate cell size-dependent decision-making of latently integrated HIV. Increases of expression bursts depend on cell size, and intracellular global resources couple into known intrinsic noise mechanisms of the HIV viral circuit ([@R18]; [@R88], [@R89]). A combination of cell size and hardwired deterministic and stochastic Tat circuitry determines stability of the latent state ([@R19]; [@R66]; [@R88], [@R89]). We show that smaller latently infected host cells are deterministically silent, while larger host-cell sizes exhibit larger expression bursts. Larger bursts lead to threshold crossings of viral products, feedback activation, and stochastic decision-making. While the dependence of burst size on cell size may eventually reach an upper limit before the power function reaches infinity, this did not occur within the range of cell sizes observed.

From an integrated gene circuit and stochastic decision-making perspective, this study presents an example of a cell size-based fate decision, consistent with reports of increasing gene expression burst size with cell reaction volume ([@R9]; [@R61]). These observations may guide strategies for viral therapies by influencing both cell size and cell cycle. Redistributing latent cells toward smaller sizes and later cell-cycle phases (for smaller B and F) (Figures [1D](#F1){ref-type="fig"} and[5A](#F5){ref-type="fig"}) would provide a potential strategy for therapies aiming to stabilize latency (e.g., block-and-lock strategy) ([@R47]). Conversely, modulating latent cell populations toward larger cell size and earlier G1 phase (for larger B and F) would benefit strategies aiming to reactivate cells from latency (e.g., shock and kill) ([@R2]).

The existence of cell size-based decision-making of an integrated viral circuit may contribute to current biomarker and therapeutic efforts in disease. It may also advance efforts to engineer noise by elucidating how cell state influences gene expression fluctuation intrinsic to gene circuits and networks for cellular decisions. Engineering noise toward forward stochastic design would benefit synthetic biology and bioengineering applications ([@R17]). The a *priori* knowledge relating cell size and viral decision-making provides insight into the mechanisms of viral-host control and a basis for sorting and characterizing cell sub-populations likely to harbor latent HIV.

Collectively, these findings present HIV as a viral gene circuit with stochastic decision-making based on mammalian host-cell size. Large cells with increased burst size are required for reactivation of latent cells. Furthermore, cell growth presents a naturally timed noise generator capable of providing asynchronous stochastic decisions in a defined cell size window for each cell. In a study, Wang and colleagues report the importance of cell growth, size, and division state memory in quiescence-exit heterogeneity ([@R86]). This study of tissue repair and tissue engineering presents an additional example of growth-dependent stochastic switching. Cell size-based gene expression programs may be of interest for multicellular systems and synthetic biology applications.

Quiescence exit and reactivation from latency suggest the existence of a broader class of cell size-based decisions in diverse cell types and biological contexts ([@R3]). These may include development and patterning in tissue growth ([@R55]), pluripotent gene expression and stem cell differentiation ([@R77]; [@R80]), intratumor heterogeneity ([@R8]; [@R35]), and circadian clock-based stochastic gene expression programs ([@R10]). Furthermore, the consistent relationship measured for housekeeping promoters in Jurkats ([Figure S1](#SD1){ref-type="supplementary-material"}) and fibroblasts ([@R61]) suggests that size-dependent gene regulation and decision-making may be fairly common and exploited throughout the genome in diverse pathways, viral-host interactions, and organisms. Evidence of cell size-dependent increases of global genome-wide bursts suggests that in addition to Tat feedback of HIV, signaling mechanisms are likely involved in the decision observed, which are not accounted for in the current model.

Strategies using host-cell size and cell cycle for monitoring and controlling latency may support drug treatments for HIV-infected individuals. The combined modulation of cell size and cell cycle provides a space for stochastic design of drug therapies ([@R19]; [@R17]). Reports demonstrate difficulty in eradicating the latent reservoir using drug treatments in HIV-infected individuals on ART due to the proliferation and expression of reactivated latent cells ([@R90]). Cell-cycle states display a large range of overlapping cell sizes and mRNA levels, allowing the independent modulation of cell size and cell-cycle phase ([@R25]; [@R61]). Checkpoint regulators may provide novel targets for controlling latent stability in larger cells. HIV is already known to stall the cell from entering mitosis by controlling G2 arrest with its viral protein vpr ([@R1]), when viral promoter activity is highest ([@R33]). The a *priori* knowledge that reactivation events occur with higher probability in larger cell sizes, while remaining silent in smaller cells, provides a paradigm for diagnostics for HIV-infected individuals, latency-reversal treatments, and therapeutic strategies toward a cure.

STAR⋆METHODS {#S10}
============

CONTACT FOR REAGENT AND RESOURCE SHARING {#S11}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Roy Dar (<roydar@illinois.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S12}
--------------------------------------

### Cell Culture and Cell Lines {#S13}

Jurkat cells and primary CD4+ T cells were grown in RPMI 1640 media supplemented with L-glutamine, 10% fetal bovine serum (FBS), and 1% Penicillin/Streptomycin (Corning Cellgro). Primary CD4+ T cells were also supplemented with 25 mM HEPES (Thermo Scientific). Cells were incubated with 5% CO2 at 37°C. Naive Jurkats and JLat isoclones 6.3, 9.2, and 15.4 were obtained from ATCC and the NIH AIDS Reagent Program. LTR-d2GFP isoclone 20 in [Figure 2](#F2){ref-type="fig"} was previously published in a noise drug screen ([@R19]) and kindly provided by the Weinberger Laboratory at the Gladstone Institute at UCSF. Infection of naive Jurkats for the production of LTR-d2GFP isoclones has been previously described ([@R18]; [@R78]). For HIV latency studies, JLat isoclones 6.3, 9.2, and 15.4 consisting of full-length HIV with GFP replacing the nef reading frame and a deletion of env were selected from a previously generated library ([@R43]). Studies with primary CD4+ T cells included the production of JLatd2GFP lentivirus containing a replication incompetent full-length HIV-1 genome with a deletion of the viral env protein and replacement of the nef reading frame by a destabilized d2GFP (Weinberger Laboratory at the Gladstone Institute at UCSF). Furthermore, T cell lines created for [Figure S1](#SD1){ref-type="supplementary-material"} consisting of the Ubc promoter with a d2GFP (UbC-d2GFP) and a LTR promoter with a d2GFP-IRES-Tat cassette (LTR-d2GFP-IRES-Tat or Ld2GIT) ([@R18]). The The JLat-d2GFP, Ld2GIT, and UbC-d2GFP plasmids were obtained from the Weinberger Laboratory at the Gladstone Institutes at UCSF.

### Isolation of Primary CD4+ cells {#S14}

Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque density gradient centrifugation of buffy coats from HIV-seronegative donors (Innovative Research, MI, USA and BioreclamationIVT, NY, USA). PBMCs were immediately processed to isolate CD4+ T cells using RosetteSep Human CD4+ T Cell Enrichment Kit (Stem Cell Technologies) and negative selection. Cultivation and stimulation of isolated CD4+ T cells was performed as previously described using a modified version of the Greene model of latency without the use of saquinavir ([@R7]; [@R50]). Subpopulations of resting and dividing CD4+ T cells were used after infection for experiments in [Figure 4](#F4){ref-type="fig"}. For activation of resting CD4+ T cells, CD3/CD28 activation beads (ThermoFisher Scientific) were used for 72h.

### Transfection of Primary Cells {#S15}

For creating primary CD4+ T cells containing the JLat-d2GFP vector, HEK293T cells, were obtained from ATCC, were tranfected with viral supernatant containing JLatd2GFP, and the viral supernatant was harvested 48h post-transfection. Infection of stimulated primary CD4+ T cells with lentiviral supernatant was performed using spinoculation and sorting was carried out as previously described ([@R7]; [@R50]). Transfection of resting primary CD4+ T cells, used a slightly modified Greene model ([@R7]) by isolating the cells using the RosetteSep human CD4+ T cell enrichment cocktail (Stemcell Technology Inc., Vancouver, Canada). Cells were then cultured in RPMI 1640 containing 10% FCS and 1% Penicillin/Streptomycin. 1 day after isolation, 2.5 × 10^6^ resting primary CD4+ T cells were spinoculated with 1:70 concentrated viral supernatant containing JLatd2GFP at 1200 x g for 2h at room temperature. Infected cells were plated at 1×10^6^ cells/ml using RPMI 1640 supplemented with 10% FCS, 1% Pencillin/Streptomycin, 25 mM HEPES, and cultured without saquinavir treatment. Single-cell fluorescence microscopy experiments of resting primary CD4+ T cells were performed either 1d after infection for samples treated with PMA+ionomycin at t = 0 of imaging or 2 days after infection for samples pretreated for 24 hour with PMA+ionomycin.

METHODS DETAILS {#S16}
---------------

### Stochastic simulations and modeling {#S17}

Stochastic simulations of the model in Figures [1](#F1){ref-type="fig"} and [5](#F5){ref-type="fig"} are implemented using the Gillespie algorithm ([@R32]). Parameters used are recorded in [Table S1](#SD1){ref-type="supplementary-material"}. A total of 1,200 units of time are simulated for each single cell and the recording interval of Tat copy number is once every 1 time unit. For modulation of fold change in B × b (Figures [1](#F1){ref-type="fig"} and [5](#F5){ref-type="fig"}), [2](#F2){ref-type="fig"}/3 of the change is attributed to decrease of k~off~, and 1/3 is attributed to increase of k~m~. To model G2 phase in cell cycle ([Figure 5](#F5){ref-type="fig"}), the number of molecule representing the gene is increased from 1 to 2 in the simulation; for G1 phase, the rate parameter k~on~ is doubled.

### Quantification of cell size versus expression burst size {#S18}

To calculate mean fluorescence \< FL \>, high-frequency noise magnitude (HF-CV^2^), and transcriptional burst size for the integrated LTR promoter as a function of cell size (or diameter), imaged cells in [Figure 2A](#F2){ref-type="fig"} were binned by their individual mean size. Next, their corresponding intensity trajectories were used for each bin size to calculate mean single-cell fluorescence, population general trends (time-dependent average of each size cluster), noise magnitude, and burst sizes using previously described noise analysis ([@R18]; [@R45]; [@R76]; [@R78]) ([Equation 1](#FD1){ref-type="disp-formula"} of main text).

### Sorting of infected primary CD4+ T cells using flow cytometry {#S19}

Three days after infection with JLatd2GFP virus and T cell stimulation, infected primary CD4+ T cells were sorted using a primary antihuman CD4 monoclonal (SIM.4) antibody (NIH AIDS Reagent Program, MD, USA) and a secondary goat anti-mouse IgG-PE antibody (Santa Cruz Biotechnology, TX, USA). Live cell staining of cells was carried out for 30 min at 4°C for the primary antibody followed by an additional step of 20 min at 4°C for the secondary antibody. Washed cells were sorted for GFP+ and GFP- populations.

### Reagents for reactivation and cell-cycle assays {#S20}

Populations of Jurkat LTR-d2GFP isoclone and JLat clones 6.3, 9.2, and 15.4 were stimulated with TNF at a final concentration of 10 ng/ml or with TNF in combination with 3 μM prostratin. Histone deacetylase inhibitor TSA (Sigma-Aldrich) was applied at a final concentration of 400nM. GFP- sorted primary CD4+ T cells were stimulated with a combination of 200 ng/ml PMA and 1 μM ionomycin. suberoylanilide hydroxamic acid (SAHA) was used at a final concentration of 2.5 μM ([@R19]; [@R49]). For cell-cycle arrest studies, JLat 15.4 and 9.2 were treated with 400 nM Rapamycin, 20 μM Resveratrol, 0.7 μM Cytarabine, and 10 μM 17β-Estradiol. For investigation of GFP-degradation rates, LTR-d2GFP isoclone 20 was treated with 10 μg/ml Cycloheximide. 3 μM Flavopiridol was used for the investigation of transcriptional bursts using LTR-d2GFP isoclone 20 ([Figure S2](#SD1){ref-type="supplementary-material"}). All chemicals were obtained from Cayman Chemicals except for TNF (R&D Systems).

### Staining of nuclei using DAPI {#S21}

JLat 9.2 was treated for 14h with 10ng/ml TNF in combination with either 2.5μM SAHA or 3μM Prostratin. Cells were washed once with 200μl PBS and fixed with 3.9% Formaldehyde (Miltenyi Biotec Inc., CA, USA) for 10 min at room temperature (RT). Afterward, cells were centrifugated at 500 x g for 5 min and 4°C and permeabilized for 30 min on ice using ice cold permeabilization buffer A (Miltenyi Biotec Inc., CA, USA). Two additional washing steps with PBS were performed after cell permeabilization, and cell nuclei were then stained with 0.1mg/ml DAPI (Sigma-Aldrich, St. Louis, USA) for 5 min in the dark at RT. After two washes with PBS, 1.5 × 105 cells were seeded into each experimental well of a half-area glass bottom 96-well plate (Corning) and imaged by taking 36 images per well using a 40x objective.

### Ratio of cytoplasm volume to nucleus volume for GFP+ cells {#S22}

Equivalent whole cell and nucleus diameters were used with the following equations under the assumption of a spherical cell: $$V_{nucleus} = \frac{\pi}{6}\left( d_{DAPI} \right)^{3},\quad V_{total} = \frac{\pi}{6}\left( d_{GFP} \right)^{3}$$ $$V_{cytoplasm} = V_{total} - V_{nucleus}\ \text{and}\mspace{9mu} Ratio_{C:N} = V_{\mathit{cytoplasm}}/V_{\mathit{nucleus}}$$

Here d~DAPI~ and d~GFP~ are the equivalent diameter calculated from their respective segmented cell areas. It is worth noting that DAPI staining involves fixation and measurements have shown that changes in the total cell area of unfixed populations are correlated with their fixed counterparts ([@R61]).

### Automated Fluorescence Imaging {#S23}

Fluorescent imaging experiments using JLats and primary CD4+ T cells were perfomed using Cell-Tak adhesive (Corning Life Science) and half-area glass-bottom 96-well plates (Corning \#4580). For imaging experiments, 1.5 × 10^5^ cells of JLat 9.2, 15.4, and 6.3 were adhered to half-area glass bottom 96-well plates using Cell-Tak adhesive (BD) and imaged for at least 20h. Long duration imaging of single primary CD4+ T cells has been proven to be challenging, and devices tailored for this purpose have been designed ([@R65]). We used a modified sample preparation with increased amounts of Cell-Tak in the glass coating layer and a decreased amount of CD4+ T cells per well (7.5 × 10^4^) to achieve 12--15h imaging experiments of stimulated CD4+ T cells from the two donors before the cells started to disengage from the glass-bottom well. Single-cell imaging of resting CD4+ T cells appeared more stable with imaging lasting 22h using increased amounts of Cell-Tak. All cell lines were imaged with a fully automated and environmentally controlled inverted Nikon Ti-Eclipse Microscope with Perfect Focus System (PFS), 20x or 40x objective, 100ms exposure, 16-bit ORCA-FLASH 4.0 CMOS camera (Hamamatsu) using 2×2 binning for 12--28h durations. Cell media with activator treatment was added at the start of imaging. Imaging utilized a stage top environmental control at 37°C and 5% CO~2~ (Tokai Hit). Periodic and automated image acquisition of multiple points within multiple wells at 10 min imaging intervals was executed using a high-speed linear motorized stage controlled by Nikon Elements software (Nikon Instruments Inc.). To reduce background fluorescence and increase imaging sensitivity, phenol-red-free RPMI 1640 medium (GIBCO) was substituted for the culturing RPMI 1640 media at the final step of imaging in all experiments.

### Data processing {#S24}

Image processing and tracking of identified single-cells was performed using Nikon Elements software with high content imaging module (Nikon Instruments Inc.). Exported data files including tracked single-cell intensity trajectories and equivalent cell diameters calculated from the processed image binary areas were processed and quantified for reactivation event detection using custom MATLAB codes (Mathworks) ([@R18]). The total number of GFP+ cells within multiple wells at various time points of imaging were calculated using segmented binary cell areas. Quality controls were performed for cells that were both DAPI and GFP positive to ensure the overlapping area is at least 95% of the total DAPI area. Although similar, autofluorescence and detection thresholds were defined for each day of imaging.

Cell-cycle analysis of reactivated latent T cells {#S25}
-------------------------------------------------

For cell-cycle analysis, drug treated JLat cells were harvested, counted, and washed twice in PBS. Cells were resuspended in flow cytometry staining buffer (R&D Systems, MN, USA) at a concentration of % ≤5 × 10^5^ cells/ml and fixed with 3.9% Formaldehyde (Miltenyi Biotec Inc., CA, USA) for 10 min at RT. Cells were centrifugated at 500 x g for 5 min at 4°C, permeabilized by adding ice cold permeabilization buffer A (Miltenyi Biotec Inc., CA, USA) and incubated on ice for 30 min. After two washing steps with PBS, cells were stained with NUCLEAR-ID^®^ Red DNA Stain (ENZO Life Sciences Inc., NY, USA) using a 1:1,000-fold dilution. Stained cells were incubated at RT for 30 min. At least 3k reactivated stained cells were collected and analyzed with a BD LSR Fortessa flow cytometer. Cell-cycle distributions are shown as the percentage of cells containing G1, S, and G2 DNA by PE-Cy5-A staining analyzed by FCS Express cell-cycle analysis software (*De Novo* Software, CA, USA).

*In silico* quantification of infected primary CD4+ T cells {#S26}
-----------------------------------------------------------

*In silico* gating of small and large cells was carried out for HIV infected ON-sorted primary CD4+ T cells treated with different drugs for 24 to 48h. Live cell populations containing 10k cells were defined as small and large cells by gating \~3k cells for each region of interest using low and high forward-scatter (FSC) from flow cytometry. For ON-sorted primary CD4+ T cells, mean fluorescence intensity was calculated by creating an ON-gate for the live cell population. The small and large FSC gated subpopulations were part of the ON-gate. Using an ON-gate allows the exclusion of cells with dim fluorescence intensities which could be sorted into the ON-sorted population. The mean GFP intensity versus FSC for each subpopulation was plotted.

CD69 receptor staining of T cell activation {#S27}
-------------------------------------------

JLat 9.2 and 15.4 were incubated 24h with 10 ng/ml TNF and washed twice with flow cytometry staining buffer (R&D Systems, MN, USA). Cells were pre-incubated with human AB serum to block nonspecific binding of the monoclonal antibody, followed by CD69 receptor staining (CD69 PE clone FN50, Thermo Fisher Scientific, MA, USA) for 30 min at 4°C using 1×10^6^ cells/100μl. The cells were washed twice in PBS and centrifugated at 500 x g for 5 min. Samples were then analyzed using a BD LSR Fortessa flow cytometry analyzer (BD Biosciences). 10k cells were collected and defined as LIVE cells. This population was used to determine small and large cells by gating \~1k cells for each region of interest using low and high forward-scatter (FSC) from flow cytometry. The mean fluorescence intensity of GFP+ cells was calculated by creating an ON-gate for the LIVE cell population. Both activated cell populations were examined for their CD69 expression and mean FCS versus PE was plotted. Previous studies using CD25 and CD69 activation markers of CD4+ T cells have also shown a lack of correlation between cell activation and cell size ([@R87]).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S28}
---------------------------------------

Mean and standard deviation were used for all cells collected in a cell size bin in [Figure 2](#F2){ref-type="fig"}. Bar plots of subsequent figures contain mean calculation of measurements with standard error based on the replicates noted in the figure caption.

For [Figure 1C](#F1){ref-type="fig"}, a two-sample Student's t test with unequal variance between the simulated cell diameter results (red bar graph) and the measured MOXI measurement (orange curve) was carried out. The p value of the test is 2:16 × 10^--124^, which shows that the difference in mean diameters between the whole population and the simulated on population is highly significant.

For [Figure 2E](#F2){ref-type="fig"}, an ANOVA test was performed after taking natural log on both x- and y axis values on our fitted model. The resulting statistical tests showed that the slope (corresponds to the power in the original non-log formula) has a p value of 7:85×10^--10^ using MATLAB built-in function anova() on our model.

Calculation of p values {#S29}
-----------------------

A two-sample t test was used to check for significance of cell-cycle-dependent differences in synergistic reactivation with TNF treatment. The first result for the significance of cell-cycle phases G1, G1/S (n = 11, SD = 2.97) and S (n = 2, SD = 0.25) shows a p value of 0.003. The second result of p = 0.03 for the same hypothesis is based on the same samples for G1, G1/S and G2, G2/M (n = 5, SD = 2.77). Differences were considered statistically significant if the p value was less than 0.05. Significance was indicated as \* for p \< 0.05 and \*\* for p \< 0.01.
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![Model for Cell Size-Based Decision-Making in HIV\
(A) (Upper) Simplified 2-state LTR promoter expressing the viral transactivator Tat. The promoter switches between inactive and actively transcribing states. At very low activity levels due to large k~off~ (large arrow), low levels of Tat result in inactive feedback. (Lower) Increases in cell size and burst size are shown as k~off~ decreases and k~m~ increases, resulting in increased Tat expression beyond threshold levels for active positive feedback.\
(B) Stochastic simulations of Tat protein levels over time for the model shown in (A), with 500 single cells simulated for small and large cell sizes. Smaller cells remain in an OFF state with inactive feedback (gray), while larger cells increase to higher Tat levels and initiate positive feedback (red).\
(C) Mean diameter distribution for cells that surpass Tat protein threshold levels in (B) for a range of simulated cell sizes (red) after normalization by an experimentally determined diameter distribution of a population of Jurkat T cells (orange and average dashed line).\
(D) Threshold-based model for size-dependent feedback. The noise versus mean protein model lines are described in [Equation 1](#FD1){ref-type="disp-formula"}. Smaller cells reside on a lower model line, and after treatment with an activator that increases burst frequency into the actively transcribing state, small cells fall short of threshold levels needed for reactivation (dashed line). Conversely, activated larger cells with larger burst size are able to fully reactivate.\
Simulation parameters used in this figure are displayed in [Table S1](#SD1){ref-type="supplementary-material"}.](nihms-1517598-f0002){#F1}

![Burst Size of the HIV LTR Promoter Increases with T Cell Volume\
(A) 3,037 single-cell intensity trajectories from anLTR-d2GFP clonal cell line acquired using 14 hr of time-lapse fluorescence microscopy. Trajectories are binned into ten groups according to their average individual equivalent diameters over the experiment. Average equivalent diameter of each bin is noted.\
(B) Analysis of binned cell trajectories reveals increased total fluorescent intensity (blue circles) and constant fluorescent concentration (orange squares) with increasing cell diameter. Mean and SD of each bin is plotted.\
(C and D) Noise magnitude (C) increases with fluorescence and transcriptional burst size (D) increases to 5- to 10-fold in larger cells compared to smaller cells. Total burst size (D) is plotted as defined in [Equation 2](#FD2){ref-type="disp-formula"}.\
(E) Power function fit to total burst size. The fold change in total burst size of the LTR promoter increases with cell diameter with a power coefficient of 5.6 (R^2^ = 0.99).\
Error bars in (B)--(D) represent the SDs within each bin.](nihms-1517598-f0003){#F2}

![Time-Lapse Fluorescence Microscopy of Latently Infected Cells Reveals Size-Dependent Reactivation of Larger Cells\
(A) 5-hr snapshots of reactivation of latent T cells infected with full-length HIV (JLat construct, upper) and imaged at 10-min intervals over 20 hr following treatment with TNF-α. Lower row shows image segmentation used to quantify single reactivation events. Cell intensity, area, and equivalent diameter are collected over time.\
(B) Mean cell intensity versus time for 500 detected reactivation events collected from a single well of JLat 9.2 after TNF-α addition. Only the first 4 hr detected for each cell trajectory is shown. Intensity durations tracked for \<4 hr were excluded from the analysis.\
(C) Distributions of JLat 9.2, 15.4, and 6.3 reactivation after 24 hr of imaging and a 4-hr detection window post-reactivation. Reactivated cells shift to a larger cell size regime compared to the total size distribution of the JLat population, which includes GFP-- cells (solid orange curve). No reactivation is detected from smaller cells below the average population diameter (dashed line).\
(D) GFP+ cell size distributions of reactivated JLat 9.2 cells treated with diverse activators for 20--24 hr show reactivation events exclusively larger than 12 μm.\
(E) Design of the reactivation experiment using TNF-α+Pro and TNF-α+SAHA for 14 hr followed by measurement of nucleus size. Snapshots of reactivated JLat 9.2 after TNF-α+SAHA treatment and DAPI staining. The left image represents a raw image of DAPI-stained and reactivated GFP+- expressing T cells. The right shows image segmentation of single cells quantifying reactivation events (red, GFP pixels in green box) and the DAPI-stained DNA content in the nucleus (purple, DAPI pixels within green box).\
(F) GFP-- (gray) and GFP+ (red) JLat 9.2 T cells DAPI stained after 14 hr of treatment with TNF-α+Pro and TNF-α+SAHA.\
(G) Reactivated GFP+ cells from (F) show a positive correlation of nucleus diameter with total cell diameter.\
(H) Cytoplasm-to-nucleus volume ratio is plotted versus total cell volume for \>5,500 GFP+ reactivation events from (F). Reactivated cell volume is dominated by nucleus volume of about twice the calculated cytoplasm volume ([STAR Methods](#S10){ref-type="sec"} and inset). The inset represents \>98% of collected single cells for each treatment.\
See also [Figures S5, S6, and S9](#SD1){ref-type="supplementary-material"}.](nihms-1517598-f0004){#F3}

![Reactivation of Latently Infected Primary CD4+ T Cells Occurs in Larger Cells\
(A) 12- to 15-hr time-lapse microscopy of OFF sorted primary cells infected with a JLatd2GFP vector (upper). Cells are treated with PMA+ionomycin at t = 0 hr, and single-cell reactivation events are quantified ([Video S2](#SD3){ref-type="supplementary-material"}). Two reactivating cells are tracked and indicated with arrows in 1-hr snapshots (scale bar, 10 μm).\
(B) Distributions of reactivated primary CD4+ T cells from two donors (upper and lower) shift to a larger size regime compared to their respective total population size distribution (black curve with average dashed line). The average size of resting CD4+ T cells is also indicated (gray curve and gray dashed line). No reactivation was detected in smaller sizes of the activated CD4+ cells.\
(C) Single-cell microscopy of resting and activated primary CD4+ T cells infected with JLatd2GFP and treated with either PMA+ionomycin at t = 0 or pretreated for 24 hr reveals cell-size-dependent reactivation between the start and the end of imaging. (Left) Resting primary cells do not reactivate between 4 and 18 hr. In contrast, stimulated primary CD4+ T cells show an increase of reactivation events (GFP+) over time. (Right) Cell-size dependence of CD4+ T cells in activated cells (red) and resting cells (gray).](nihms-1517598-f0005){#F4}

![Reactivation of T Cells Latently Infected with HIV Is Cell-Cycle Dependent\
(A) Hypothesis of the effect of cell cycle on reactivation after activator treatment. With higher k~on~ in G1 phase, cells move farther on the model line of noise versus mean viral expression after activator treatment ([Equation 1](#FD1){ref-type="disp-formula"}). This results in an increase of reactivated cells compared to G2 phase with the same treatment.\
(B) Model of the effect of cell cycle on HIV-positive feedback by accounting for differences of cell-cycle phase represented by changes in k~on~ and copy number of the feedback circuit.\
(C) Stochastic simulation results for cells with elevated Tat levels and active feedback for 500 simulated cells for each cell diameter and cell-cycle phase. The bars represent a 5-point moving average of the distribution. Both G1 and G2 phases are shifted to the right from the total population distribution, with the G1 peak \~75% higher than G2.\
(D) Comparison of cell-cycle distributions of the entire cell population and reactivated cells (GFP+) for JLat 9.2 after 12 hr of treatment with TNF-α and TNF-α+SAHA. Cells reactivate at different levels for G1 and G2, suggesting cell-cycle-dependent reactivation.\
(E) Ratios of reactivated to total cells in G1, S, and G2 are calculated by separately dividing the normalized frequency of the cell-cycle distributions in (D). A 9-point moving average of the TNF-α-treated trend reveals an increase in reactivation of \~4× in G1 compared to the expected reactivation events from a cell-cycle-independent assumption (ratio = 1). Except for an absent G1 peak, SAHA+TNF-α follows a trend similar to that of TNF-α alone.\
See also [Figure S9](#SD1){ref-type="supplementary-material"} and [Table S1](#SD1){ref-type="supplementary-material"}.](nihms-1517598-f0006){#F5}

![Modulation of Cell Cycle Alters Reactivation of Latent Cells\
(A) (Left) Experiment design using treatments with diverse cell-cycle-arresting drugs. Cell cycle was arrested for 24 hr for JLat 9.2 and 15.4, and reactivation was performed with 12-hr TNF-α after cell-cycle arrest. Cell cycle was determined by DNA staining using flow cytometry. (Right) Cell cycle of Jurkat cells is arrested for 24 hr using rapamycin, resveratrol, cytarabine, and 17β-estradiol.\
(B--E) Alteration of cell-cycle progression and reactivation of cells after treatment with rapamycin (B), resveratrol (C), cytarabine (D), and 17β-estradiol (E) in combination with TNF-α. The table for TNF-α only is shown above. Cell-cycle arrest causes reactivation of cells at specific phases (the largest GFP+ arrest phase is highlighted with rectangles).\
(F) Reactivation of JLat 9.2 and 15.4 after the treatment design shown in (A).\
(G) Similar reactivation with simultaneous combination of cell-cycle arrester with TNF-α for 24-hr treatments.\
(H) Dependence of synergistic reactivation on cell cycle with TNF-α treatment is confirmed by previously characterized noise enhancers known to affect cell cycle ([@R19]). In the previous study, measurements of 24-hr treatment of JLat 8.6 with noise enhancers and TNF-α show highest reactivation in G1 phase, followed by G1/S and G2/M cell populations (mean reactivation in parentheses).\
Calculated p values (\*p \< 0.05 and \*\*p \< 0.005) indicate significance between reactivation of treatment groupings by cell-cycle phase. Bar plots represent a mean and SE of two experiments.](nihms-1517598-f0007){#F6}
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  REAGENT or RESOURCE                                             SOURCE                                                   IDENTIFIER
  --------------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------------------------------------
  Antibodies                                                                                                               

  DAPI Nuclear Stain                                              Sigma-Aldrich                                            D9542

  NUCLEAR-ID^®^ Red DNA Stain                                     ENZO Life Science Inc.                                   Cat\# EWZ-51008--100

  Anti-human CD69 monoclonal antibody (PE), clone FN50            Thermo Fisher Scientific                                 Cat\# 12--0699-73; RRID: AB_465735

  Anti-human CD4 monoclonal antibody (SIM.4)                      NIH AIDS Reagent Program                                 Cat\# 724

  Goat anti-mouse IgG-PE                                          Santa Cruz Biotechnology                                 Cat\# sc-3738

  Biological Samples                                                                                                       

  Single Donor Human Whole Blood                                  Innovative Research                                      Cat\# IPLA-WB1

  Single Donor Human Whole Blood                                  BioreclamationIVT                                        Biofluids (Blood-derived), Human whole blood

  Chemicals, Peptides, and Recombinant Proteins                                                                            

  Tumor Necrosis Factor alpha (TNF)                               R&D Systems                                              Cat\# 210-TA-005

  Propidium iodide (PI)                                           Thermo Fisher Scientific                                 Cat\# P3566

  Phorbol 12-myristate 13-acetate (PMA)                           Cayman Chemical                                          Cat\# 10008014

  Human Interleukin 2 (IL-2)                                      Miltenyo Biotec Inc                                      Cat\# 130--097-742

  Flavopiridol                                                    Cayman Chemical                                          Cat\# 10009197

  Prostratin (Pro)                                                Cayman Chemical                                          Cat\# 10272

  Cycloheximide                                                   Cayman Chemical                                          Cat\# 14126

  Trichostatin A (TSA)                                            Cayman Chemical                                          Cat\# 89730

  Suberoylanilide hydroxamic acid (SAHA)                          Cayman Chemical                                          Cat\# 10574

  Ionomycin                                                       Cayman Chemical                                          Cat\# 10004974

  Rapamycin                                                       Cayman Chemical                                          Cat\# 53128--88-9

  *trans*-Resveratrol                                             Cayman Chemical                                          Cat\# 70675

  Cytarabine (S-phase arrest)                                     Cayman Chemical                                          Cat\# 16069

  Critical Commercial Assays                                                                                               

  Permeabilization Buffer (Cell Signaling Buffer Set A)           Miltenyi Biotec Inc.                                     Cat\# 130--100-827

  3.9% Fixation Buffer Inside Fix (Cell Signaling Buffer Set A)   Miltenyi Biotec Inc.                                     Cat\# 130--100-827

  Cell-Tak Cell and Tissue Adhesive                               Corning Life Science                                     Cat\# 354241

  Dynabeads Human T-Activator CD3/CD28                            Thermo Fisher Scientific                                 Cat\# 11161D

  RosetteSep Human CD4+ T cell Enrichment Cocktail                StemCell Technologies, Inc.                              Cat\# 15022

  FuGENE6 Transfection Reagent                                    Promega                                                  Cat\# E2691

  Experimental Models: Cell Lines                                                                                          

  JLat 6.3                                                        NIH AIDS Reagents Program, ([@R43])                      Cat\# 9846

  JLat 9.2                                                        NIH AIDS Reagents Program, ([@R43])                      Cat\# 9848

  JLat 15.4                                                       NIH AIDS Reagents Program, ([@R43])                      Cat\# 9850

  HEK293T                                                         ATCC                                                     ATCC CRL-3216

  Naive Jurkats, clone E6--1                                      ATCC                                                     ATCC TIB-152

  Recombinant DNA                                                                                                          

  JLat-d2GFP (NL4.3. DeltaEnv-d2GFP)                              Weinberger Lab (Gladstone Institutes),([@R36]; [@R66])   N/A

  UbC-d2GFP                                                       Weinberger Lab (Gladstone Institutes),([@R18])           N/A

  LTR-d2GFP isoclone 20                                           Weinberger Lab (Gladstone Institutes),\                  N/A
                                                                  ([@R19])                                                 

  LTR-d2GFP polyclonal                                            Weinberger Lab (Gladstone Institutes),\                  N/A
                                                                  ([@R18], [@R19])                                         

  LTR-d2GFP-IRES-Tat                                              Weinberger Lab (Gladstone Institutes),\                  N/A
                                                                  This paper                                               

  Software and Algorithms                                                                                                  

  Nikon Elements Software                                         Nikon Instruments Inc.                                   <https://www.nikoninstruments.com/Products/Software/NIS-Elements-Advanced-Research>

  MATLAB                                                          MathWorks                                                <https://www.mathworks.com/>
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###### Highlights

-   Gene expression bursts from the HIV LTR promoter increase with T cell size

-   Larger T cells latently infected with HIV exclusively reactivate from latency

-   Reactivation from HIV latency is cell-cycle dependent, with enhancement in G1

-   Checkpoint arrestors actively modulate cell cycle to bias viral decision-making
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